Cargando…

Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma

BACKGROUND: Combinations of drugs can improve the efficacy of cancer treatment, enable the reduction of side effects and the occurrence of acquired drug resistance. METHODS: We approached this challenge mathematically by using the validated technology called the Therapeutically Guided Multidrug Opti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rausch, Magdalena, Weiss, Andrea, Achkhanian, Joanna, Rotari, Andrei, Nowak-Sliwinska, Patrycja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435198/ https://www.ncbi.nlm.nih.gov/pubmed/32439932 http://dx.doi.org/10.1038/s41416-020-0890-y

Ejemplares similares

Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance
por: Rausch, Magdalena, et al.
Publicado: (2020)

Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma
por: Rausch, Magdalena, et al.
Publicado: (2021)

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
por: Rausch, Magdalena, et al.
Publicado: (2021)

Characterization of Renal Cell Carcinoma Heterotypic 3D Co-Cultures with Immune Cell Subsets
por: Rausch, Magdalena, et al.
Publicado: (2021)

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma
por: Zoetemelk, Marloes, et al.
Publicado: (2019)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
por: Mohammad, H., et al.
Publicado: (2021)

Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer
por: Hany, Dina, et al.
Publicado: (2023)

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
por: Powles, Thomas, et al.
Publicado: (2008)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib
por: Frees, Sebastian, et al.
Publicado: (2018)

Forcing dividing cancer cells to die; low‐dose drug combinations to prevent spindle pole clustering
por: Ducrey, Eloise, et al.
Publicado: (2021)

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
por: Harmon, Charles S., et al.
Publicado: (2013)

Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
por: Weiss, Andrea, et al.
Publicado: (2019)

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
por: Billemont, B, et al.
Publicado: (2008)

A case of metastatic renal cell carcinoma treated effectively by gemcitabine and sunitinib
por: Morizane, Shuichi, et al.
Publicado: (2012)

Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma
por: Domagała-Haduch, Małgorzata, et al.
Publicado: (2016)

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
por: Gu, Cheng-Yuan, et al.
Publicado: (2021)

Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma
por: Greenberg, Jacob W., et al.
Publicado: (2021)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
por: Fiala, Ondřej, et al.
Publicado: (2021)

Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition
por: Nowak-Sliwinska, P, et al.
Publicado: (2015)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization
por: Weiss, Andrea, et al.
Publicado: (2014)

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
por: Rini, Brian I., et al.
Publicado: (2011)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
por: Beuselinck, B, et al.
Publicado: (2013)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
por: Keizman, Daniel, et al.
Publicado: (2016)

Acute Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib
por: da Fonseca, Leonardo Gomes, et al.
Publicado: (2014)

Conditional disease-free survival in high-risk renal cell carcinoma treated with sunitinib
por: Shao, Ning, et al.
Publicado: (2019)

Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression
por: Berndsen, Robert H., et al.
Publicado: (2019)

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study
por: Tullemans, Bibian M. E., et al.
Publicado: (2022)

Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
por: Maráz, Anikó, et al.
Publicado: (2018)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
por: Guo, Jun, et al.
Publicado: (2018)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient
por: Choo, Hun Gu, et al.
Publicado: (2021)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5d32g279bqte4sace4d44tl6do